Synopsis of recent research by authors named "Jenna O Walls"
- Jenna O Walls' recent research focuses on the implications of pan-cancer testing for mismatch repair deficiency (dMMR) following the FDA's approval of pembrolizumab, extending the significance of MMR immunohistochemistry (IHC) beyond Lynch syndrome screening.
- The study reviews MMR IHC reports from an academic hospital between 2017 and 2021, assessing the completion rates of genetic testing and the outcomes of these tests in a real-world setting.
- Findings indicate a broader application of genetic testing in various tumor types, emphasizing the importance of dMMR assessment in guiding treatment options, particularly in immunotherapy.